|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The Appendix May Protect Against Clostridium difficile Recurrence显示文摘 | Gene Y. Im Rani J. Modayil Cheng T. Lin Steven J. Geier Douglas S. Katz Martin Feuerman James H. Grendell | 2011 | Clinical Gastroenterology and Hepatology2011，，12： | 1 |
| 2 | The Appendix May Protect Against Clostridium difficile Recurrence显示文摘 | Gene Y. Im Rani J. Modayil Cheng T. Lin Steven J. Geier Douglas S. Katz Martin Feuerman James H. Grendell | 2011 | Clinical Gastroenterology and Hepatology2011，，12： | 1 |
| 3 | Evaluation and Selection of the Patient with Alcoholic Liver Disease for Liver Transplant显示文摘 | Jennifer Leong Gene Y. Im | 2012 | Clinics in Liver Disease2012，，4： | 1 |
| 4 | High yield of same-session EUS-guided liver biopsy by 19-gauge FNA needle in patients undergoing EUS to exclude biliary obstruction显示文摘 | Stavros N. Stavropoulos Gene Y. Im Zahra Jlayer Michael D. Harris Teodor C. Pitea George K. Turi Peter F. Malet David M. Friedel James H. Grendell | 2012 | Gastrointestinal Endoscopy2012，，2： | 1 |
| 5 | Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus显示文摘AIM: To determine the safety profile of new hepatitis C virus(HCV) treatments in liver transplant(LT) recipients with recurrent HCV infection.METHODS: Forty-two patients were identified with recurrent HCV infection that underwent LT at least 12 mo prior to initiating treatment with a Sofosbuvir-based regimen during December 2013-June 2014. Cases were patients who experienced hepatic decompensation and/or serious adverse events(SAE) during or within one month of completing treatment. Controls had no evidence of hepatic decompensation and/or SAE. HIVinfected patients were excluded. Cumulative incidence of decompensation/SAE was calculated using the Kaplan Meier method. Exact logistic regression analysis was used to identify factors associated with the composite outcome. RESULTS: Median age of the 42 patients was 60 years [Interquartile Range(IQR): 56-65 years], 33%(14/42) were female, 21%(9/42) were Hispanic, and 9%(4/42) were Black. The median time from transplant to treatment initiation was 5.4 years(IQR: 2.1-8.8 years). Thirteen patients experienced one or more episodes of hepatic decompensation and/or SAE. Anemia requiring transfusion, the most common event, occurred in 62%(8/13) patients, while 54%(7/13) decompensated. The cumulative incidence of hepatic decompensation/SAE was 31%(95%CI: 16%-41%). Risk factors for decompensation/SAE included lower pre-treatment hemoglobin(OR = 0.61 per g/d L, 95%CI: 0.40-0.88, P < 0.01), estimated glomerular filtration rate(OR = 0.95 per m L/min per 1.73 m^2, 95%CI: 0.90-0.99, P = 0.01), and higher baseline serum total bilirubin(OR = 2.43 per mg/d L, 95%CI: 1.17-8.65, P < 0.01). The sustained virological response rate for the cohort of 42 patients was 45%, while it was 31% for cases.CONCLUSION: Sofosbuvir/ribavirin will continue to be used in the post-transplant population, including those with HCV genotypes 2 and 3. Management of anemia remains an important clinical challenge. | Neal Patel Kian Bichoupan Lawrence Ku Rachana Yalamanchili Alyson Harty Donald Gardenier Michel Ng David Motamed Viktoriya Khaitova Nancy Bach Charissa Chang Priya Grewal Meena Bansal Ritu Agarwal Lawrence Liu Gene Im Jennifer Leong Leona Kim-Schluger Joseph Odin Jawad Ahmad Scott Friedman Douglas Dieterich Thomas Schiano Ponni Perumalswami Andrea Branch | 2016 | World Journal of Gastroenterology2016，22，9： | 1 |
| 6 | Real-world cure rates for hepatitis C virus treatments that include simeprevir and/or sofosbuvir are comparable to clinical trial results显示文摘AIM To assess the real-world effectiveness and cost of simeprevir(SMV), and/or sofosbuvir(SOF)-based therapy for chronic hepatitis C virus(HCV) infection.METHODS The real-world performance of patients treated with SMV/SOF ± ribavirin(RBV), SOF/RBV, and SOF/RBV with pegylated-interferon(PEG) were analyzed in a consecutive series of 508 patients with chronic HCV infection treated at a single academic medical center. Patients with genotypes 1 through 4 were included. Rates of sustained virological response-the absence of a detectable serum HCV RNA 12 wk after the end of treatment [sustained virological response(SVR) 12]-were calculated on an intention-to-treat basis. Costs were calculated from the payer's perspective using Medicare/Medicaid fees and Redbook Wholesale Acquisition Costs. Patient-related factors associated with SVR12 were identified using multivariable logistic regression.RESULTS SVR 12 rates were as follows: 86%(95%CI: 80%-91%)among 178 patients on SMV/SOF ± RBV; 62%(95%CI: 55%-68%) among 234 patients on SOF/RBV; and 78%(95%CI: 68%-86%) among 96 patients on SOF/PEG/RBV. Mean costs-per-SVR 12 were $174442(standard deviation: ± $18588) for SMV/SOF ± RBV; $223003(± $77946) for SOF/RBV; and $126496(± $31052) for SOF/PEG/RBV. Among patients on SMV/SOF ± RBV, SVR12 was less likely in patients previously treated with a protease inhibitor [odds ratio(OR): 0.20, 95%CI: 0.06-0.56]. Higher bilirubin(OR: 0.47, 95%CI: 0.30-0.69) reduced the likelihood of SVR12 among patients on SOF/RBV, while FIB-4 score ≥ 3.25 reduced the likelihood of SVR 12(OR: 0.18, 95%CI: 0.05-0.59) among those on SOF/PEG/RBV. CONCLUSION SVR 12 rates for SMV and/or SOF-based regimens in a diverse real-world population are comparable to those in clinical trials. Treatment failure accounts for 27% of costs. | Kian Bichoupan Neeta Tandon James F Crismale Joshua Hartman David Del Bello Neal Patel Sweta Chekuri Alyson Harty Michel Ng Keith M Sigel Meena B Bansal Priya Grewal Charissa Y Chang Jennifer Leong Gene Y Im Lawrence U Liu Joseph A Odin Nancy Bach Scott L Friedman Thomas D Schiano Ponni V Perumalswami Douglas T Dieterich Andrea D Branch | 2017 | World Journal of Virology2017，6，4： | 1 |
| 7 | Therapy as an adjuvant treatment for malignant gliomas: from bench to bedside 显示文摘 | Germano IM Binello E GENE | 2009 | Journal of Neuro - Oncology2009，93，1： | 1 |
| 8 | Evaluation and Selection of the Patient with Alcoholic Liver Disease for Liver Transplant显示文摘 | Jennifer Leong Gene Y. Im | 2012 | Clinics in Liver Disease2012，，4： | 1 |
| 9 | 伊莎贝拉蝶显示文摘在2002年上映的法国电影《蝴蝶》里,朱利安跋山涉水去寻觅一只名叫“伊莎贝拉”(Isabellae)的蝴蝶,影片唯美地再现了伊莎贝拉破茧成蝶的过程。从外观上看,伊莎贝拉酷似蝴蝶,人们也俗称其为蝶。其实,从生物学的意义上说,“伊莎贝拉”并不是蝶,而是蛾。 | 宁麦 Banco de im genes del CNICE-MECá | 2017 | 环球人文地理2017，0，9： | 0 |
| 10 | Importance and Risk Prediction of ABO Blood Group and Rh Factor in Papillary Thyroid Cancer显示文摘Objective:There are limited data in the literature regarding the potential relationship between thyroid cancer and ABO blood types and Rh factor.The aim of our study was to investigate whether papillary thyroid cancer(PTC)is associated with blood type.Materials and Methods:The present study included patients who presented to Dicle University Faculty of Medicine between June 2009 and December 2020 and were diagnosed with PTC as a result of postoperative(thyroidectomy)histopathological analysis.The control group consisted of individuals whose blood type was analyzed at a random blood center.Results:Of the 223 patients diagnosed with PTC,163(73.1%)were females and 60(26.9%)were males.In the comparison of patients based on ABO blood types and Rh factor,A Rh positive blood type was found 31%less frequently in the PTC group compared with the control group,and thus it was associated with a lower risk of PTC(OR:0.69;95%Confidence Interval:0.50-0.96,p=0.029).Conclusions:In our study,we found A Rh positive blood type to be significantly less frequent among patients with PTC.A Rh positive blood type can be considered as a protective factor indicating a reduced risk of PTC. | Dilek Geneş Zafer Pekkolay MehmetŞimşek Hüsna Saraçoğlu Mehmet Turgut Alpaslan Kemal Tuzcu | 2022 | Journal of Endocrinology Research2022，4，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员